書目名稱 | LH-RH Agonists in Oncology | 編輯 | Klaus H?ffken | 視頻video | http://file.papertrans.cn/581/580095/580095.mp4 | 圖書封面 |  | 描述 | Hormonal treatment of malignant diseases came of age quite some years ago. Nevertheless, developments in this field are still progressing at a steady pace. During recent years, the detection of new endocrine feedback loops and the availability of new classes of hormonal agents made it possible to predictively interfere with hor- mone actions. Besides the intellectual challenge of modulating the hormone system, there is an important new aspect associated with recent research on hormones and cancer: new developments have generally led to a reduction in treatment-induced morbidity. As aromataseinhibitors are substituted for adrenalectomy, controlled interference with the hypothalamic-gonadotrophic axis is likely to replace surgical removal of the relevant glands, i. e. , the pituitary gland or the gonads. With the detection of the luteinizing hormone releasing hormone (LH-RH), its structural analysis, and the synthesis of analogs of this decapeptide hormone, a tool became available not only for treatment of sterility or endometriosis but also for switching off gonadal activity in a reversible manner. Evidence has accumulated over the past few years that LH-RH agonists can serve as "me | 出版日期 | Conference proceedings 1988Latest edition | 關(guān)鍵詞 | Gonadotropin; cancer; carcinoma; chemotherapy; clinical trial; fertility; hormone; hormones; infertility; onc | 版次 | 1 | doi | https://doi.org/10.1007/978-3-642-73530-1 | isbn_softcover | 978-3-642-73532-5 | isbn_ebook | 978-3-642-73530-1 | copyright | Springer-Verlag Berlin Heidelberg 1988 |
The information of publication is updating
|
|